Pharmaceuticals

MSI-H And dMMR Market Outlook 2026–2030 Highlighting Emerging Business Opportunities

March 23, 2026March 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The MSI-H And dMMR Market During The Forecast Period 2026–2030?

The msi-h and dmmr market has experienced substantial growth in recent years. Its value is anticipated to rise from $7.57 billion in 2025 to $9.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.1%. This historical expansion can be attributed to several factors, including the identification of msi-h and dmmr biomarkers, the early success observed with immune checkpoint inhibitors, the increasing incidence of colorectal and endometrial cancer, the wider availability of molecular diagnostics, and the regulatory approvals granted for therapies based on biomarkers.

The market size for msi-h and dmmr is projected to experience substantial expansion over the coming years, anticipated to reach $21.13 billion by 2030 with a compound annual growth rate (CAGR) of 22.7%. This growth during the forecast period is attributable to the increasing adoption of precision oncology, the wider application of genomic testing in cancer care, the broadening of immunotherapy indications, a surge in investment in biomarker research, and the accumulation of clinical evidence supporting tumor-agnostic approaches. Key trends anticipated in the same period involve the rising uptake of immunotherapy for msi-h and dmmr tumors, the expanding role of companion diagnostics in patient stratification, a heightened emphasis on tumor-agnostic cancer therapies, the proliferation of combination immunotherapy regimens, and enhanced recognition of biomarker-driven oncology.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which Major Factors Are Driving The Expansion Of The MSI-H And dMMR Market?

The increasing occurrence of cancer is projected to drive the expansion of the MSI-H and dMMR market in the future. Cancer encompasses a collection of illnesses defined by the uncontrolled proliferation and dissemination of atypical cells throughout the body. The growing incidence of cancer can largely be attributed to aging demographics, as the probability of developing cancer rises considerably with age due to the combined effect of genetic alterations and extended exposure to risk factors over time. Within cancer treatment, MSI-H and dMMR are employed to pinpoint tumors exhibiting elevated mutation rates stemming from deficiencies in DNA repair mechanisms. These specific biomarkers are instrumental in directing immunotherapy choices, given that such tumors often show a greater likelihood of responding to immune checkpoint inhibitors, and they also offer valuable information regarding prognosis and possible genetic syndromes. For example, in January 2024, data from the American Cancer Society, a US-based non-profit organization, indicated that in 2023, an estimated 1,958,310 new cancer cases and 609,820 cancer-related deaths were expected in the United States. These figures are forecast to increase in 2024, with approximately 2,001,140 new cancer cases and 611,720 deaths anticipated, underscoring an ongoing rise in both cancer incidence and mortality. Consequently, the rising prevalence of cancer is a key factor stimulating the growth of the MSI-H and dMMR market.

What Market Segments Are Evaluated Within The MSI-H And dMMR Market?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Industry Trends Are Redefining The MSI-H And dMMR Market?

Leading companies active in the MSI-H and dMMR market are concentrating on creating advanced treatments, such as combination therapy, to boost treatment effectiveness and better patient results. This strategy for MSI-H and dMMR cancers entails employing two or more treatment methods, frequently including immunotherapy agents like checkpoint inhibitors, or combining immunotherapy with chemotherapy, targeted therapy, or radiation. The goal is to improve treatment response, circumvent resistance, and prolong survival in individuals whose tumors display high microsatellite instability or deficient mismatch repair. As an illustration, in April 2025, the US-based pharmaceutical company, Bristol-Myers Squibb Company, secured United States Food and Drug Administration (FDA) approval for its nivolumab (Opdivo) and ipilimumab (Yervoy) combination as a primary treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) characteristics, thereby expanding therapeutic choices for this complex cancer subtype. This approval represents a pivotal achievement in the management of MSI-H and dMMR cancers, providing a novel, potent therapeutic alternative that addresses various pathways to elevate patient survival and response rates, thus meeting significant unmet medical requirements within this patient demographic.

Who Are The Top Market Participants Influencing The MSI-H And dMMR Market?

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Read the full msi-h and dmmr market report here:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Region Currently Holds The Largest Share Of The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored MSI-H And dMMR Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2026, By The Business Research Company

Automotive Human Machine Interface Hmi Market Report 2026

https://www.thebusinessresearchcompany.com/report/automotive-human-machine-interface-hmi-global-market-report

Electronic Data Interchange Edi Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/electronic-data-interchange-edi-software-global-market-report

Digital Aerospace Mro Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-aerospace-mro-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795